KISQALI® is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This means the cancer has grown outside the breast and spread to the lymph nodes in the area of the breast (locally advanced) or has spread to other parts of the body (metastatic). KISQALI® is used in combination with the following when treating advanced or metastatic breast cancer:

an aromatase inhibitor as the first endocrine-based therapy; or
fulvestrant as the first endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men

Here's where you can explore helpful tools and resources to support you on your KISQALI® treatment journey

Information brochure

A comprehensive brochure that can help you understand your breast cancer diagnosis. Inside, you'll find important information about KISQALI^® and useful lifestyle tips.

Download

Treatment tracker

Keep track of your KISQALI^® treatment one day at a time with this handy calendar.

Download

Wallet card

This wallet-sized card may help your healthcare team have a better understanding of any potential symptoms you may be experiencing.
You can show it whenever you visit a hospital/pharmacy or clinic.

Download

If you prefer to have a physical copy of any of these resources, you can print the digital PDFs.

Here's where you can explore helpful tools and resources to support you on your KISQALI® treatment journey

Information brochure

Treatment tracker

Wallet card

Here are some sources of information that you might find helpful:

National:

Provincial: